Currently, the treatment for HBV infection suffers from adverse side effects
and drug resistance. The dramatic development of new HBV inhibitors is focused on
discovering diverse non-nucleoside compounds with either novel structures or new
mechanisms of action. Capsid assembly is crucial to the completion of the viral life
cycle, which makes it an attractive target for antivirus discovery. Inhibitors that block
the formation of the HBV capsid have been developed, and several candidates have
been proposed. In this review, we focus on the recent advances in several distinct classes of synthetic small molecular
non-nucleosides targeting at the capsid assembly.
Keywords: HBV, inhibitors, non-nucleosides, small synthetic molecules, capsid assembly.
Rights & PermissionsPrintExport